- Home
- APVO vs RDHL Comparison
APVO vs RDHL Comparison
Compare APVO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- RDHL
- Stock Information
- Founded
- APVO 2016
- RDHL 2009
- Country
- APVO United States
- RDHL Israel
- Employees
- APVO N/A
- RDHL N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- RDHL Health Care
- Exchange
- APVO Nasdaq
- RDHL Nasdaq
- Market Cap
- APVO 4.1M
- RDHL 3.8M
- IPO Year
- APVO N/A
- RDHL N/A
- Fundamental
- Price
- APVO $3.23
- RDHL $1.85
- Analyst Decision
- APVO Strong Buy
- RDHL
- Analyst Count
- APVO 1
- RDHL 0
- Target Price
- APVO $5,920.00
- RDHL N/A
- AVG Volume (30 Days)
- APVO 6.6M
- RDHL 18.5K
- Earning Date
- APVO 08-07-2025
- RDHL 04-10-2025
- Dividend Yield
- APVO N/A
- RDHL N/A
- EPS Growth
- APVO N/A
- RDHL N/A
- EPS
- APVO N/A
- RDHL N/A
- Revenue
- APVO N/A
- RDHL $8,042,999.00
- Revenue This Year
- APVO N/A
- RDHL $381.91
- Revenue Next Year
- APVO N/A
- RDHL N/A
- P/E Ratio
- APVO N/A
- RDHL N/A
- Revenue Growth
- APVO N/A
- RDHL 23.17
- 52 Week Low
- APVO $2.81
- RDHL $1.71
- 52 Week High
- APVO $485.37
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- APVO 34.28
- RDHL 43.03
- Support Level
- APVO $2.81
- RDHL $1.72
- Resistance Level
- APVO $13.11
- RDHL $2.08
- Average True Range (ATR)
- APVO 1.10
- RDHL 0.09
- MACD
- APVO 0.30
- RDHL 0.01
- Stochastic Oscillator
- APVO 4.08
- RDHL 27.78
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.